A systematic review of the therapeutic applications of cannabidiol (CBD) and nabiximols, a whole plant extract of C. sativa containing equal parts CBD and tetrahydrocannabinol (THC), was published in the Journal of Cannabis Research. The authors of the review found 23 relevant studies where CBD and nabiximols was used to treat a host of psychiatric disorders. These compounds were most effective at treating schizophrenia, social anxiety disorder, autism spectrum disorder, attention deficit hyperactivity disorder, and even cannabis withdrawal and moderate to severe cannabis use disorder. They were less effective at treating insomnia, anxiety, bipolar disorder, post-traumatic stress disorder, and Tourette syndrome. The researchers believe more studies are needed to confirm these findings.
To read the full article, click here.